Literature DB >> 25684772

Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12.

Lilian H van Tuyl1, Martina Sadlonova1, Bev Davis1, Caroline Flurey1, Niti Goel1, Sarah E Hewlett1, Catherine L Hill1, Wijnanda Hoogland1, John R Kirwan1, Dirkjan van Schaardenburg1, Marieke Scholte-Voshaar1, Josef S Smolen1, Tanja Stamm1, George A Wells1, Maarten Boers1.   

Abstract

OBJECTIVE: The treatment of rheumatoid arthritis (RA) should target patient-relevant outcomes, making patient perspective on remission essential. In 2010, patients, physicians, health professionals, and researchers at the Outcome Measures in Rheumatology (OMERACT) conference developed an ambitious research agenda to study the concept of remission. Qualitative research has since helped us understand the concept of remission from the patient perspective.
METHODS: During OMERACT 12, the OMERACT working group on patient perspective on remission in RA elaborated on data generated to date and discussed the methodological challenges ahead. Challenges included (1) selection of domains, (2) choice of a patient remission definition or a single domain to add to the current remission definition, and (3) the importance of pain in defining remission from a patient perspective.
RESULTS: Focus in the coming years will be on increasing our understanding by identifying the most important domains from the patient perspective regarding remission and investigating how these domains can be measured. Investigation into the Rheumatoid Arthritis Impact of Disease questionnaire, disease flare, as well as the concordance of domains from our ongoing remission survey is appropriate. More data and further discussions are needed to decide on the next steps.
CONCLUSION: Progress summarized over 4 years highlights the main methodological challenges discussed within the working group on patient perspective on remission in RA during OMERACT 12.

Entities:  

Keywords:  OMERACT; PATIENT PERSPECTIVE; PATIENT-REPORTED OUTCOME; REMISSION; RHEUMATOID ARTHRITIS

Mesh:

Year:  2015        PMID: 25684772     DOI: 10.3899/jrheum.141113

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Incorporating the patient's perspective in outcomes research.

Authors:  Betty Hsiao; Liana Fraenkel
Journal:  Curr Opin Rheumatol       Date:  2017-03       Impact factor: 5.006

2.  Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.

Authors:  M Elaine Husni; Keith A Betts; Jenny Griffith; Yan Song; Arijit Ganguli
Journal:  Rheumatol Int       Date:  2017-06-16       Impact factor: 2.631

3.  Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.

Authors:  D Vinson; L Molet-Benhamou; Y Degboé; A den Broeder; F Ibrahim; C Pontes; R Westhovens; J Závada; T Pham; T Barnetche; A Constantin; A Ruyssen-Witrand
Journal:  Arthritis Res Ther       Date:  2020-04-29       Impact factor: 5.156

4.  Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis.

Authors:  Generoso Guerra Bautista; Ricardo Machado Xavier; Maria de la Vega; J Abraham Simón-Campos; Gastón Solano; Ronald D Pedersen; Bonnie Vlahos; Cecilia Borlenghi
Journal:  Open Access Rheumatol       Date:  2019-12-12

5.  Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.

Authors:  Hema Chaplin; Lewis Carpenter; Anni Raz; Elena Nikiphorou; Heidi Lempp; Sam Norton
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

6.  Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.

Authors:  Vibeke Strand; Eun Bong Lee; Roy Fleischmann; Rieke E Alten; Tamas Koncz; Samuel H Zwillich; David Gruben; Bethanie Wilkinson; Sriram Krishnaswami; Gene Wallenstein
Journal:  RMD Open       Date:  2016-09-28

7.  What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis.

Authors:  Kristien Van der Elst; Elke G E Mathijssen; Ellen Landgren; Ann Bremander; An De Groef; Elisabet Lindqvist; Maria Nylander; Alma Peters; Frank Van den Hoogen; Yvonne van Eijk-Hustings; Gerard Verhoeven; Johanna E Vriezekolk; Rene Westhovens; Ingrid Larsson
Journal:  RMD Open       Date:  2020-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.